Press Release
26 November 2026 12:50:00 CET

PILA PHARMA AB
Norra Vallgatan 72, 211 22 Malmö, Sweden
www.pilapharma.com.com

PILA PHARMA: CORPORATE PRESENTATION AT AKTIESPARARNA, TODAY NOVEMBER 26 TO UPDATE ON ONGOING OBESITY TRIAL

26 November 2026, Malmö, Sweden: PILA PHARMA AB (publ)(FN STO: PILA)(FRA: 5KC), a clinical stage biotech company pioneering development of an oral TRPV1 antagonist as a potential first-in-class treatment for obesity and diabetes, will present today at Aktiespararna (The Swedish Shareholders Association) to provide an update on the ongoing activities around the Company's lead candidate, the oral TRPV1 antagonist XEN-D0501, currently being investigated in the clinical trial PP-CT04, in people living with obesity.

26 November: Aktiespararna (in-person and recording)
Stockholm, Sweden, 18:05-18:25 CET
Link: **https://www.aktiespararna.se/aktiviteter/stora-aktiedagarna-i-stockholm-68179**

PILA PHARMA also presented yesterday, November 25 at Økonomisk Ugebrev in Copenhagen, Denmark. Once available, the recordings from both events will be shared.

Latest on PP-CT04
In August 2026, PILA PHARMA received regulatory approval to conduct PP-CT04, a two-part, randomised, double-blind, placebo-controlled 12-week trial of XEN-D0501 in people living with obesity. The clinical site was activated in September and in October 2026 the first participants were dosed in the initial safety cohort of Part 1.

For those who missed the latest interview, it was conducted with BioStock during BIO-Europe in Cologne. Here our CEO Gustav H. Gram shared his impressions from the partnering floor, how XEN-D0501 stands out as an oral TRPV1-targeting alternative to the GLP-1 drugs, and gave an update on the PP-CT04 study following the first participants being dosed.

Link: **https://biostock.se/en/2026/11/bio-europe-i-gang-pila-pharma-sticker-ut-bland-glp-1-lakemedlen-och-ger-en-uppdatering/**

PILA PHARMA AB
Norra Vallgatan 72, 211 22 Malmö, Sweden
www.pilapharma.com.com

_____

To stay up to date on news, events & where to meet us, please see our website:
https://www.pilapharma.com/

For more information:

Gustav H. Gram, CEO
ghg@pilapharma.com

PILA PHARMA's share ticker PILA is subject to trade on Nasdaq First North Growth Market, Sweden with Aqurat Fondkommission AB as Certified Adviser. Contact: M: **ca@aqurat.se** - T: +46 (0)8 684 05 800

About PILA PHARMA AB (Publ)

PILA PHARMA AB is a Swedish clinical stage biotech company based in Malmö, Sweden. The aim of the company is to develop TRPV1 antagonists as a novel treatment of obesity and diabetes. The Company owns a TRPV1 asset with data and chemical entities including the clinical development candidate XEN-D0501. In August 2026, the Company had a clinical trial application approved for a new 12-week clinical trial in people living with obesity. The clinical trial PP-CT04 started in September 2026 and is presently ongoing. The Company moreover holds an orphan drug designation ("ODD") for XEN-D0501 as a treatment for the painful rare disease erythromelalgia.